Molecular detection of MBL and better risk prediction through immune and protein profiling
Official title: Molecular detection of MBL and enhanced risk stratification through immunogenetic and proteomic profiling.
Funded at Erasmus Medical Center · NIH-11453390 · Data updated 2026-11-12
This research aims to use blood DNA sequencing plus immune protein information to detect early B-cell changes that can lead to CLL, helping adults over 40 understand their risk.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Erasmus Medical Center NIH-funded |
| Lab location | 1 site (Rotterdam, NETHERLANDS) |
| Project start | July 20, 2026 |
| Project end | June 30, 2031 |
| Funding year | 2026 |
| Award (this year) | $511,551 |
| NIH project number | 1R01CA309413-01A1 |
| Project ID | NIH-11453390 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults over 40 who are at risk for or suspected of having MBL or CLL based on initial clinical findings.
✕Less likely to help
People without MBL or CLL or those not undergoing blood-based genetic testing may not benefit.
What this research studies
The project focuses on monoclonal B-cell lymphocytosis (MBL), a precursor to CLL, and explores whether sequencing the IGH gene from whole blood can replace labor-intensive flow cytometry for screening. Researchers will compare IGH-based clonality detection with the current flow cytometry gold standard to see if it accurately identifies MBL. They will also use advanced single-cell sequencing to study transcriptome patterns that might signal progression toward CLL. The study will involve adults over 40 and analyze blood samples to build better risk stratification models that could guide monitoring and early interventions from a patient perspective.
Why it matters
Potential benefit: If successful, patients could benefit from simpler screening and better prediction of who might progress to CLL, enabling earlier care and targeted follow-up.
How similar studies have gone: Previous work shows IGH sequencing can reveal B-cell clonality, but this study directly compares it to flow cytometry for MBL in a large US-based context.
Where this research is happening
-
Erasmus Medical Center
Rotterdam, Netherlands Active
Researchers
- Principal investigator: Langerak, Anton W — Erasmus Medical Center
- Study coordinator: Langerak, Anton W
Related research
Other NIH-funded projects on the same topics.
-
Understanding how bird flu viruses switch to highly dangerous forms
Researchers are studying how bird flu viruses change to become highly dangerous in poultry to help prevent outbreaks that harm animals and people.
-
Understanding how bird flu viruses become highly dangerous
This study looks at how certain bird viruses can change and become more dangerous, which is important for keeping both birds and people safe from illness, and it aims to help us understand and stop future outbreaks.
-
Understanding why some patients fail treatment with dolutegravir for HIV
This study is looking into why some people with HIV in Brazil aren't responding to the medication dolutegravir, by checking for certain changes in the virus that might be causing this issue, so we can find better ways to help everyone manage their treatment.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.